In the last decade, significant strides have been made in the field of drug discovery and development, driven by the rapid advancements in multi-omics technologies. Multi-omics, encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenomics, has emerged as a powerful approach to unravel the complexity of diseases and identify novel therapeutic targets. Genomic studies have unveiled genetic variations associated with drug responses, leading to the development of pharmacogenomics-based strategies for personalized drug prescriptions. Additionally, transcriptomic analysis has shed light on disease-related pathways and gene expression profiles, guiding the discovery of new drug targets and repurposing existing drugs for novel indications. Furthermore, proteomics has played a pivotal role in characterizing protein interactions, posttranslational modifications, and drug-protein interactions, aiding in the development of targeted therapies and the optimization of drug candidates. Metabolomics, on the other hand, has offered insights into the dynamic metabolic changes associated with disease states. Moreover, the application of epigenomics has provided crucial information on epigenetic modifications, uncovering potential druggable epigenetic targets that could influence disease progression. In conclusion, the integration of multi-omics approaches has revolutionized drug discovery and development, allowing for the identification of personalized therapeutic strategies and the acceleration of precision medicine initiatives. This comprehensive review aims at providing an overview of the various multi-omics applications in drug development and highlights their impact.